Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Soared 109.8% In January

By Rich Duprey - Feb 5, 2021 at 2:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hope for an oral COVID-19 vaccine remains alive.

What happened

Shares of Vaxart (VXRT 7.14%) surged 109.8% in January, according to data provided by S&P Global Market Intelligence, adding onto the colossal 1,530% gain the stock made across all of 2020.

So what

Essentially a penny stock at the start of last year, Vaxart vaulted to the forefront of investor consciousness on the premise that it could develop an effective oral vaccine for COVID-19.

Prescription bottle and pills

Image source: Getty Images.

So far, both of the COVID-19 vaccines approved for emergency use by the FDA require patients to receive two injections, and both must be stored and shipped at extremely cold temperatures. They also have relatively short shelf lives.

Many members of the public would doubtless prefer to receive their vaccination via a pill. Moreover, Vaxart's tablet is shelf-stable at room temperature, which removes some major logistical hurdles to distribution.

Now what

Shares of the stock really took off again toward the end of the month as the biotech was preparing to update the market on how its phase 1 vaccine candidate was performing. Unfortunately, based on that update, it doesn't appear that Vaxart's pill will meet the goal of being a one-dose solution.

VXRT Chart

VXRT data by YCharts

According to the report released just days ago, subjects given a single dose of Vaxart's vaccine didn't produce neutralizing antibodies for the coronavirus. However, study participants who took two doses 29 days apart did produce them, so there is still hope for the biotech company's candidate. 

Obviously, much more will be learned as the candidate advances through later-stage clinical trials that measure its actual efficacy in preventing COVID-19. But the prospect of taking two pills a month apart still seems preferable in many ways to getting one or two jabs with a needle.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
$3.75 (7.14%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.